EyePoint Pharmaceuticals (EYPT) News Today $8.02 +0.41 (+5.39%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of "Buy" from AnalystsShares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine research firms that are presently covering the company, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The averagDecember 18 at 2:23 AM | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 6.4% - Here's WhyEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 6.4% - Here's What HappenedDecember 17 at 5:24 PM | marketbeat.comEyePoint to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17 at 10:37 AM | markets.businessinsider.comShort Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Decreases By 6.4%EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 9,250,000 shares, a drop of 6.4% from the November 15th total of 9,880,000 shares. Based on an average daily volume of 855,700 shares, the days-to-cover ratio is currently 10.8 days.December 16 at 10:19 PM | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 52-Week Low - Should You Sell?EyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 52-Week Low - Should You Sell?December 16 at 10:55 AM | marketbeat.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)December 16 at 7:00 AM | globenewswire.comPoint72 Asset Management L.P. Cuts Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Point72 Asset Management L.P. lessened its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 28.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 451,318 shares of the company's stock after selling 179,451 shares duringDecember 9, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 7% Higher - Time to Buy?EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 7% - Here's WhyDecember 6, 2024 | marketbeat.comEyePoint Pharmaceuticals Poised for Growth with Promising DME Treatment DuravyuDecember 4, 2024 | markets.businessinsider.comPatient Square Capital LP Makes New $10.88 Million Investment in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Patient Square Capital LP purchased a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,361,979 shares of the cDecember 4, 2024 | marketbeat.comEyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular DegenerationDecember 4, 2024 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Sells 71,796 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Connor Clark & Lunn Investment Management Ltd. lessened its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 59.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 48,791 shares of the company's stock after selling 71,796 sharDecember 1, 2024 | marketbeat.comEyePoint reports inducement grants under NASDAQ listing ruleNovember 18, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 8.5% - What's Next?EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 8.5% - What's Next?November 15, 2024 | marketbeat.comResearch Analysts Issue Forecasts for EYPT FY2024 EarningsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Investment analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for EyePoint Pharmaceuticals in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst Y. Chen now aNovember 14, 2024 | marketbeat.comEyePoint Pharmaceuticals: Low Price And Good Data Create An OpportunityNovember 14, 2024 | seekingalpha.comEyePoint Pharmaceuticals: Buy Rating Backed by Promising Clinical Developments and Strong Financial PositionNovember 11, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $22.00 by Analysts at HC WainwrightHC Wainwright dropped their price objective on shares of EyePoint Pharmaceuticals from $30.00 to $22.00 and set a "buy" rating for the company in a research report on Monday.November 11, 2024 | marketbeat.comRobert W. Baird Issues Pessimistic Forecast for EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock PriceRobert W. Baird reduced their target price on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating on the stock in a research note on Monday.November 11, 2024 | marketbeat.comEyePoint Pharmaceuticals Advances in Retinal TherapeuticsNovember 9, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $33.00Chardan Capital upped their price objective on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a "buy" rating in a report on Friday.November 8, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 5.4% - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 5.4% - Time to Sell?November 4, 2024 | marketbeat.comEyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNovember 4, 2024 | globenewswire.comEyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesOctober 31, 2024 | globenewswire.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Strong Trading Volume - What's Next?EyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Large Volume Increase - Here's What HappenedOctober 30, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Quotes, Forecast and News SummaryOctober 30, 2024 | benzinga.comEyePoint Pharmaceuticals Announces Pricing of Upsized Public OfferingOctober 29, 2024 | globenewswire.com‘Really competitive’ tax breaks keep EyePoint manufacturing in Mass.October 29, 2024 | bizjournals.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.5% - Should You Sell?EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 6.5% - Time to Sell?October 29, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Reaffirmed by Chardan CapitalChardan Capital restated a "buy" rating and set a $28.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Tuesday.October 29, 2024 | marketbeat.comEyePoint Pharmaceuticals Inc.October 29, 2024 | wsj.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Buy" by AnalystsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are covering the firm, Marketbeat.com reports. Nine analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated tOctober 29, 2024 | marketbeat.comEyePoint Pharmaceuticals Announces Proposed Public Offering of Common StockOctober 28, 2024 | globenewswire.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - Still a Buy?EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - Still a Buy?October 28, 2024 | marketbeat.comEyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular EdemaOctober 28, 2024 | globenewswire.comEyePoint Pharmaceuticals: Promising Growth Potential with Innovative Treatments and Strategic LeadershipOctober 25, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Rating Reiterated by HC WainwrightHC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of EyePoint Pharmaceuticals in a report on Friday.October 25, 2024 | marketbeat.comSG Americas Securities LLC Cuts Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)SG Americas Securities LLC lessened its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 74.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 19,303 shares of the company's stock after selling 56,985 shares during the period. SG AmericaOctober 25, 2024 | marketbeat.comEyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular DegenerationOctober 24, 2024 | globenewswire.comANI Pharmaceuticals price target raised to $62 from $60 at TruistOctober 22, 2024 | markets.businessinsider.comScotiabank Initiates Coverage of EyePoint Pharmaceuticals (EYPT) with Sector Outperform RecommendationOctober 17, 2024 | msn.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Now Covered by ScotiabankScotiabank began coverage on EyePoint Pharmaceuticals in a research report on Wednesday. They set a "sector outperform" rating for the company.October 16, 2024 | marketbeat.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)October 16, 2024 | globenewswire.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 9.7% - Time to Buy?EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 9.7% - Here's What HappenedOctober 14, 2024 | marketbeat.comEssex Investment Management Co. LLC Boosts Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Essex Investment Management Co. LLC grew its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 234.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 142,144 shares of the company's stock afterOctober 13, 2024 | marketbeat.comMillennium Management LLC Reduces Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Millennium Management LLC trimmed its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 71.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 580,716 shares of the company's stock after selling 1,4October 12, 2024 | marketbeat.comSquarepoint Ops LLC Has $404,000 Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Squarepoint Ops LLC decreased its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 66.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 46,456 shares of the company's stock after sOctober 11, 2024 | marketbeat.comRenaissance Technologies LLC Increases Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Renaissance Technologies LLC boosted its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 112.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 152,800 shares of the companOctober 6, 2024 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of "Buy" from AnalystsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has received an average rating of "Buy" from the eight analysts that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 1 year price objective amongOctober 4, 2024 | marketbeat.comPoint72 Asset Management L.P. Makes New $5.49 Million Investment in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Point72 Asset Management L.P. purchased a new stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 630,769 shares of the cOctober 2, 2024 | marketbeat.com Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Forbes rich list released… #1 to be assassinated? (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now EYPT Media Mentions By Week EYPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EYPT News Sentiment▼0.540.71▲Average Medical News Sentiment EYPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EYPT Articles This Week▼74▲EYPT Articles Average Week Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TRNS News CTKB News LAB News AEHR News QTRX News SENS News NAUT News QSI News FEIM News KEQU News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EYPT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EyePoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
